Immunovant (NASDAQ:IMVT) Releases Earnings Results, Misses Estimates By $0.12 EPS

Immunovant (NASDAQ:IMVT) announced its quarterly earnings data on Thursday. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.12), FiscalAI reports. The company had revenue of $7.09 million during the quarter, compared to analyst estimates of $7.09 million. During the same period in the prior year, the company posted ($0.71) EPS.

Here are the key takeaways from Immunovant’s conference call:

• Brexpiprazole’s potential dermatomyositis launch remains on track for late September following priority review, with commercial and patient-support teams in place. Management emphasized a “slow and steady” rollout focused on building access and a broader multi-indication franchise rather than maximizing early sales.
• Roivant has begun enrolling the phase III cutaneous sarcoidosis study after strong phase II results, while the lichen planus program is also enrolling well. Top-line readouts are expected in the second half of 2026 for brexpocitinib in non-infectious uveitis and povorcitinib in PH-ILD, with additional proof-of-concept data in cutaneous lupus.
• Roivant received approximately $950 million from its Moderna settlement, including roughly $772 million attributable to Genevant and Arbutus. Additional potential proceeds include about $1.3 billion from the ongoing ’498 appeal and further litigation against Pfizer and BioNTech.
• The company reported nearly $4 billion in cash before the settlement proceeds and repurchased approximately $200 million of shares during the quarter. Management said buybacks will continue under existing authorizations, citing attractive share-retirement economics.
• Management highlighted substantial execution and clinical risk in the upcoming catalysts: PH-ILD’s key question is whether povorcitinib’s pulmonary vascular effects translate from PAH, while placebo-response variability remains a concern for the NIU study. Roivant expects to provide a fuller update on difficult-to-treat rheumatoid arthritis after randomized-withdrawal data and an FDA discussion later this year.

Immunovant Price Performance

Shares of IMVT stock traded up $0.21 on Friday, reaching $39.95. 906,196 shares of the company were exchanged, compared to its average volume of 922,481. The company has a market cap of $8.25 billion, a price-to-earnings ratio of -14.17 and a beta of 0.77. The company has a 50-day moving average of $37.23 and a 200-day moving average of $30.59. Immunovant has a one year low of $14.32 and a one year high of $41.23.

Analysts Set New Price Targets

IMVT has been the topic of a number of recent research reports. Sanford C. Bernstein raised Immunovant to a “hold” rating in a research note on Wednesday, July 29th. Truist Financial boosted their target price on shares of Immunovant from $23.00 to $30.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. Guggenheim upped their price target on shares of Immunovant from $44.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Monday, July 6th. Finally, HC Wainwright lifted their price target on shares of Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immunovant has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Insider Activity

In related news, CEO Eric Venker sold 3,092 shares of Immunovant stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $38.48, for a total value of $118,980.16. Following the completion of the sale, the chief executive officer owned 254,280 shares of the company’s stock, valued at approximately $9,784,694.40. This trade represents a 1.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Atul Pande sold 1,500 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $38.01, for a total transaction of $57,015.00. Following the completion of the sale, the director owned 116,731 shares in the company, valued at $4,436,945.31. This represents a 1.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 324,810 shares of company stock valued at $11,350,166. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of Immunovant

A number of hedge funds have recently bought and sold shares of the business. Empowered Funds LLC lifted its position in Immunovant by 4.5% in the 4th quarter. Empowered Funds LLC now owns 14,175 shares of the company’s stock worth $360,000 after buying an additional 610 shares in the last quarter. Wellington Management Group LLP grew its stake in Immunovant by 2.7% in the fourth quarter. Wellington Management Group LLP now owns 28,847 shares of the company’s stock valued at $733,000 after purchasing an additional 755 shares in the last quarter. Royal Bank of Canada grew its stake in Immunovant by 20.7% in the fourth quarter. Royal Bank of Canada now owns 4,549 shares of the company’s stock valued at $116,000 after purchasing an additional 780 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Immunovant by 2.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,124 shares of the company’s stock worth $578,000 after purchasing an additional 900 shares during the last quarter. Finally, Nuveen LLC increased its position in Immunovant by 0.6% in the 4th quarter. Nuveen LLC now owns 226,489 shares of the company’s stock worth $5,757,000 after purchasing an additional 1,449 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.